Spectral Med Inc is seeing a positive uptick in its stock price, gaining 2.21% in the last trading session, closing at CA$1.39.
In a notable move on the TSX, Spectral Med Inc (EDT.TO) has experienced a 2.21% increase in its stock price during the last trading session. This rise comes amid ongoing developments in the company's clinical trials and financial strategies, which are capturing the attention of investors.
Advertisement
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeAdvertisement
Market cap
$407.85M
52W high
$1.84
52W low
$0.97
1W change
-1.42%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 126.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+126.6% Upside
Current Price
C$1.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
27.0%
Annualized
90-Day Vol
28.5%
Annualized
Trend (90d)
-6.0%
Annualized drift
90d Mean
C$1.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.38 | C$1.26 – C$1.51 |
| 60 trading days | C$1.37 | C$1.20 – C$1.56 |
| 90 trading days | C$1.36 | C$1.16 – C$1.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should keep an eye on Spectral Med's advancements in clinical trials and its financial maneuvers, as these could significantly impact its market performance in the near future.
Spectral Med Inc Market Cap
With a market cap of CA$399 million, Spectral Med Inc is positioned as a significant player in the biotech sector, but it still faces challenges in demonstrating consistent revenue generation.
Bull case
The recent publication of the Tigris trial results in The Lancet Respiratory Medicine has reaffirmed the effectiveness of Spectral's PMX-20R treatment. This could boost investor confidence and spark more interest in the market.
Bear case
Despite the positive movement, investors should remain cautious. The company has yet to achieve profitability, and how the market reacts to future trial results could be unpredictable.
Advertisement
Positive Trial Results Boost Investor Confidence
The recent publication of the Tigris trial results has confirmed positive outcomes for Spectral's PMX-20R treatment, which could significantly reduce 28-day mortality rates. This news has likely contributed to the stock's upward movement as investors react to the potential for future market success.
Financial Strategies and Market Position
Spectral Med's recent non-dilutive financing arrangements with Vantive, which include up to US$10 million, provide a strong financial backbone as the company prepares for commercialization. This financial strategy may enhance investor confidence, reinforcing the stock's positive trajectory.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
